The authors confirmed that the DC–RCC hybrid stimulated CD4+ and CD8+ T cells to produce IFN-γ, and vaccination of patients with the DC–RCC hybrid resulted in decreased tumor size [136]. This evidence concerns the gene CD8A and renal cell carcinoma.